We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+35.04%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$181M
Cap. Flow
+$126M
Cap. Flow %
6.49%
Top 10 Hldgs %
41.59%
Holding
123
New
29
Increased
30
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$28.3M
2
ANAB icon
AnaptysBio
ANAB
+$26.6M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$20.4M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$19.6M
5
ERAS icon
Erasca
ERAS
+$17.1M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$58.6M
2
WVE icon
Wave Life Sciences
WVE
+$16.9M
3
CGEM icon
Cullinan Oncology
CGEM
+$14.8M
4
ACLX
Arcellx
ACLX
+$14.2M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.51%
2 Miscellaneous 13.84%
3 Financials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVI icon
26
Trevi Therapeutics
TRVI
$2.39B
$23.9M 1.23%
2,000,172
-150,000
-7% -$1.68M
OVID icon
27
Ovid Therapeutics
OVID
$547M
$23.6M 1.22%
10,636,318
+3,486,318
+49% +$6.23M
ELVN icon
28
Enliven Therapeutics
ELVN
$4.24B
$23M 1.19%
+586,904
New +$16.3M
ASND icon
29
Ascendis Pharma A/S
ASND
$16.3B
$21.7M 1.12%
95,000
+65,000
+217% +$14.6M
MLYS icon
30
Mineralys Therapeutics
MLYS
$2.26B
$20.3M 1.05%
750,000
+20,000
+3% +$587K
AVTX icon
31
Avalo Therapeutics
AVTX
$1.05B
$20M 1.03%
1,340,840
+289,786
+28% +$4.53M
BMY icon
32
CALL
Bristol-Myers Squibb
BMY
$136B
$18.2M 0.94%
+300,000
New +$17.5M
PTGX icon
33
Protagonist Therapeutics
PTGX
$9.34B
$18.1M 0.94%
172,125
– –
CLDX icon
34
Celldex Therapeutics
CLDX
$3.07B
$15.9M 0.82%
500,000
+150,000
+43% +$4.09M
ZURA icon
35
Zura Bio
ZURA
$548M
$15.3M 0.79%
2,564,303
+750,632
+41% +$4.53M
NRIX icon
36
Nurix Therapeutics
NRIX
$2.72B
$15M 0.77%
967,620
– –
SVRA icon
37
Savara
SVRA
$1.08B
$13.7M 0.71%
2,512,153
-285,000
-10% -$1.59M
CATX icon
38
Perspective Therapeutics
CATX
$355M
$13.2M 0.68%
3,164,582
+2,864,582
+955% +$12.1M
HLXC
39
Helix Acquisition Corp III
HLXC
$238M
$12.7M 0.66%
+1,250,000
New +$12.8M
ARWR icon
40
Arrowhead Research
ARWR
$12B
$12.5M 0.65%
200,000
+130,000
+186% +$8.23M
DMRA
41
Damora Therapeutics
DMRA
$1.79B
$11.7M 0.6%
+450,000
New +$11.6M
EPRX
42
Eupraxia Pharmaceuticals
EPRX
$441M
$11.5M 0.59%
1,589,005
+1,289,005
+430% +$10.4M
ANRO icon
43
Alto Neuroscience
ANRO
$1.38B
$11.2M 0.58%
+500,000
New +$9.27M
BBIO icon
44
BridgeBio Pharma
BBIO
$15B
$11.1M 0.58%
150,000
-170,000
-53% -$12.3M
CGEM icon
45
Cullinan Oncology
CGEM
$1.4B
$11.1M 0.57%
781,260
-1,150,846
-60% -$14.8M
BLTE
46
Belite Bio
BLTE
$6.11B
$10.4M 0.54%
65,000
+45,000
+225% +$7.57M
WVE icon
47
Wave Life Sciences
WVE
$993M
$10.2M 0.52%
1,401,727
-1,298,273
-48% -$16.9M
VERA icon
48
Vera Therapeutics
VERA
$2.46B
$10.1M 0.52%
250,000
– –
TYRA icon
49
Tyra Biosciences
TYRA
$1.49B
$9.86M 0.51%
+257,512
New +$8.34M
RVMD icon
50
Revolution Medicines
RVMD
$44.6B
$9.72M 0.5%
100,000
– –
1
2
3 4 5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Affinity Asset Advisors held 123 positions worth $1.94B, up 10% from $1.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors deployed $126M of net new capital in Q1 2026, opening 29 new positions and adding to 30 existing holdings. Its largest new stake was Enliven Therapeutics: 586,904 shares worth $23M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 77% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Wave Life Sciences, an estimated $16.9M trimmed.

  • Affinity Asset Advisors's largest Q1 2026 buy was Enliven Therapeutics: 586,904 shares worth $23M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q1 2026, an estimated $28.3M increase.
  • Affinity Asset Advisors's biggest Q1 2026 reduction was Wave Life Sciences, cutting an estimated $16.9M.
  • Affinity Asset Advisors fully exited Ventyx Biosciences in Q1 2026, selling an estimated $58.6M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.94B portfolio in Q1 2026.
  • Affinity Asset Advisors opened 29 new positions and closed 18 in Q1 2026.
  • Affinity Asset Advisors's portfolio value rose 10% quarter-over-quarter to $1.94B.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.